Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Trends Mol Med. 2022 Dec;28(12):1112-1127. doi: 10.1016/j.molmed.2022.09.001. Epub 2022 Oct 5.
Asthma exacerbations significantly impact millions of patients worldwide to pose large disease burdens on affected patients, families, and health-care systems. Although numerous environmental factors cause asthma exacerbations, viral respiratory infections are the principal triggers. Advances in the pathophysiology of asthma have elucidated dysregulated protective immune responses and upregulated inflammation that create susceptibility and risks for exacerbation. Biologics for the treatment of severe asthma reduce rates of exacerbations and identify specific pathways of inflammation that contribute to altered pathophysiology, novel therapeutic targets, and informative biomarkers. Major steps to prevent exacerbations include the identification of molecular pathways whose blockage will prevent asthma attacks safely, predictably, and effectively.
哮喘恶化严重影响了全球数以百万计的患者,给患者、家庭和医疗保健系统带来了巨大的疾病负担。虽然许多环境因素可导致哮喘恶化,但病毒性呼吸道感染是主要诱因。哮喘病理生理学的进步阐明了失调的保护性免疫反应和炎症上调,这为恶化创造了易感性和风险。用于治疗严重哮喘的生物制剂可降低恶化率,并确定导致病理生理学改变、新治疗靶点和有意义的生物标志物的炎症特定途径。预防恶化的主要步骤包括确定分子途径,其阻断将安全、可预测和有效地预防哮喘发作。